Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 4/20 | 0.37 |
| ▸ | F13A1 | P00488 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | TGM1 | P22735 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 8/20 | 0.36 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26630335 | 1.00 | GSK3B (0.41) | GSK3BEGFRF13A1TGM2TGM1 | |
| SCHEMBL26630288 | 0.92 | GSK3B (0.41) | GSK3BEGFRF13A1TGM2TGM1 | |
| SCHEMBL26630283 | 0.92 | GSK3B (0.41) | GSK3BEGFRF13A1TGM2TGM1 | |
| SCHEMBL26630379 | 0.89 | BRD4 (0.38) | GSK3BEGFRF13A1TGM2TGM1 | |
| SCHEMBL26630373 | 0.89 | BRD4 (0.38) | GSK3BEGFRF13A1TGM2TGM1 | |
| SCHEMBL26630296 | 0.88 | EGFR (0.45) | GSK3BEGFRF13A1TGM2TGM1 | |
| SCHEMBL26630303 | 0.88 | EGFR (0.45) | GSK3BEGFRF13A1TGM2TGM1 | |
| SCHEMBL26630376 | 0.88 | EGFR (0.35) | GSK3BEGFRF13A1TGM2TGM1 | |
| SCHEMBL26630369 | 0.88 | EGFR (0.35) | GSK3BEGFRF13A1TGM2TGM1 | |
| SCHEMBL26630233 | 0.84 | TEAD2 (0.35) | GSK3BEGFRF13A1TGM2TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2025-09-11 | — | — | US | disclosed |
| EP-4514780-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | Dong-A ST Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023209651-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | TEAD1, TEAD2, TEAD3 | GSK3B 245/4885EGFR 3961/4885F13A1 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.